Attendee search 

Valkee Oy is a health technology company founded in 2007 that has developed a bright light headset device for treatment of Seasonal Affective Disorder. The knowhow of the company is based on long term scientific research and development work together with the Oulu University.

The Valkee Bright Light Headset substitutes the mood-elevating effects of the sun, by channeling safe bright light directly to photosensitive regions of the brain through the ear canal. That's why Valkee increases energy, and can act as a preventative or treatment of mood swings. Valkee has CE Class II(a) medical device certification and is clinically tested.

We want to improve the quality of life for 660.000 epilepsy families. (# is the western world only)

We want to give New Freedom and Peace of Mind to patients, parents, and health care professionals.

IctalCare A/S develops and markets a body-worn wireless epilepsy seizure alarm that help people with epilepsy, caregivers and healthcare professional

IctalCare 365 consist of a;
- Disposable electrode
- Reusable detector "Senses"
- Reusable A-Unit (receiver and transmitter)

Timeline;
- Launch 12.12.12 at 12.12 pm in Denmark
- Launch 12th of April 2013 in UK and Germany
- Launch 12th of April 2014 in USA
- Exit 2016

Finance;
- Expected revenue in 2016 is € 23 Million
- Positive cash flow from 2014 - 2015
- Expected EBITDA is € 9.3 Million in 2016 having a gross Margin of 55 %

Business Model
We have Sustainable Competitive Advantage using the Razor blade Model. The disposable electrodes secures a continuous sale and only IctalCare electrodes fit to the reusable "Senses" detector.

The Business Model is designed around a monthly subscription Model however buy on demand will also be possible

Likvor AB

Likvor is a medical device company which has developed a system to be used in neurological investigations assessing cerebrospinal fluid (CSF) dynamics. The LIKVOR CELDA® SYSTEM is on the market today.

Product

Likvor’s core product, the CELDA® Instrument is a device to measure the dynamics of the cerebrospinal fluid (“CSF”) system. With increased understanding of the brain and neurological diseases, mapping CSF dynamics is becoming more and more important. CELDA® Instrument offers automatic and standardized protocols for multiple purposes in the diagnostic process – identifying patients suffering from normal pressure hydrocephalus (“NPH”) with dementia like symptoms, mapping CSF dynamics pre- and post-shunt surgery, shunt control, constant flow or constant pressure measurements, tap tests, bolus infusions etc. It is the first and only CE certified instrument in this field and will enable objective comparisons of research data from different clinics and research groups. With its flexibility and easy handling the CELDA® sets a new standard for investigations of CSF-dynamics. CELDA® Instrument is safer for the patient and yields a faster and more accurate diagnosis.

By using the LIKVOR CELDA® SYSTEM hospitals can make huge savings, in costs as they reduce the number of shunt reoperations, and in human suffering.

Likvor AB is marketing the LIKVOR CELDA® SYSTEM and LIKVOR CELDA® TOOLS. The system includes an instrument, a bed and a disposable tube set. The system is the result of over 40 years of research at Umeå University and Umeå University Hospital assessing cerebrospinal fluid (CSF) dynamics. The company has one patent in the US and two patents pending which includes both method and device.

Potential and the market

Statistics show that 1 in 10 dementia patients suffer from NPH. Studies indicate that approximately 1.4 million patients in Europe, USA and Japan suffer from NPH.

The CELDA® SYSTEM was CE certified in 2009, and currently there are 8 systems in clinical use with paying customers in Sweden, Denmark, Finland and the UK. To reach the European market, distributors will be used, two contracts are signed; for the German- and the UK-market. A potential clinical study in the US is being evaluated.

Next step

Likvor is looking for 20 MSK for the next three years. The capital will be used to speed up the market penetration in Europe and recruit sales personnel. Exit could be possible through an industrial buyout, for example from a shunt company.  

Inven2 is the TTO of the University of Oslo and Oslo University Hospital. Inven2 commercializes annually 25-30 inventions through license deals and creating start-ups. 75 % of the commercializations are within Life Science sector.

Medico Innovation is a public-private cluster organization that facilities medical device matchmaking, innovation partnerships, professional networks and innovation camps. We help innovators connect with the right experts at the right moments.